Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,170.00
Bid: 12,172.00
Ask: 12,174.00
Change: 108.00 (0.90%)
Spread: 2.00 (0.016%)
Open: 12,194.00
High: 12,266.00
Low: 12,054.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: IAG And M&B Financing Moves; Astra Pulls Drug

Mon, 22nd Feb 2021 07:54

(Alliance News) - Stock prices in London were seen opening lower on Monday, with inflationary fears souring the mood ahead of UK Prime Minister Boris Johnson laying out a roadmap to exit lockdown in England.

IG futures indicate the FTSE 100 index in London was to open 60.3 points lower at 6,563.72. The blue-chip index closed up 6.87 points, or 0.1%, at 6,624.02 on Friday.

In early corporate news, International Consolidated Airlines Group said British Airways has secured two finance-support pacts worth GBP2.45 billion in total.

AstraZeneca announced the voluntary withdrawal of its Imfinzi drug in the US for bladder cancer treatment following a recent clinical trial blow.

Among London mid-caps, Mitchells & Butlers noted a sharp fall in sales in recent months as it launched an open offer to bolster the pub operator's finances. G4S suitor GardaWorld declared as final its increased takeover offer for the security services firm, which has already agreed a GBP3.8 billion buyout from Allied Universal.

Commenting on the European market open, AvaTrade analyst Naeem Aslam commented: "There are some concerns among investors that inflation could be getting out of control. Traders believe that if the sharp rise in inflation is not addressed, higher prices may actually hurt the economic recovery. The rise in inflation is primarily due to the two main factors: loose monetary policy adopted by central banks around the world such as the Fed, the BOE, the ECB, the BOJ, and the PBOC."

The Chinese central bank has now kept its benchmark interest rate at the same level for the tenth month in a row.

The one-year loan prime rate was held at 3.85% on Monday. The last time the rate was changed was back in April. The five-year rate also was unchanged at 4.65%.

Aslam added: "So far, central banks such as the Fed, the ECB, and the BOE haven't paid much attention to this issue as they feel that inflation is still within their level of tolerance, and they can smack the inflation numbers down whenever they want. The other factor which is pushing inflation up is the sharp increase in oil prices. There is no doubt oil prices had seen a remarkable recovery, and both Crude and Brent oil prices are becoming closer to levels which we saw before the pandemic surged."

Equities in China were lower on Monday. The Shanghai Composite ended down 1.5% and Hong Kong's Hang Seng was 1.1% lower in late trade.

Elsewhere in Asia, the Nikkei 225 in Tokyo closed up 0.5%, but the S&P/ASX 200 in Sydney ended down 0.2%.

Brent oil was quoted at USD63.52 a barrel, up slightly from USD63.47 at the London equities close Friday. Safe-haven gold was quoted at USD1,791.84 an ounce, up from USD1,786.45.

Pharmaceutical firm AstraZeneca withdrew its Imfinzi drug in the US, a decision made following a consultation with the Food & Drug Administration.

Back in May 2017, the drug secured accelerated approval based on promising tumour response rates from a Phase I/II trial.

"Continued approval was contingent on results from the DANUBE Phase III trial in the 1st-line metastatic bladder cancer setting, which did not meet its primary endpoints in 2020. The withdrawal is aligned with FDA guidance for evaluating indications with accelerated approvals that did not meet post-marketing requirements, as part of a broader industry-wide evaluation. This withdrawal does not impact the indication outside the US and does not impact other approved Imfinzi indications within or outside the US," Astra added.

Security company GardaWorld "stands firm" and its 235 pence per share offer for G4S is final. GardaWorld said early Monday the offer will not be revised.

"There can be no better owner for G4S than GardaWorld, but we are disciplined buyers and we will not overpay for a company with systemic ESG issues that continue to come to light," GardaWorld Chief Executive Stephan Cretier said.

The 235p offer values G4S at GBP3.68 billion.

Earlier in February, London's Takeover Panel stepped in to put in place an auction procedure to resolve an ongoing takeover saga.

Last month, G4S agreed to be taken over by Allied Universal in a GBP3.8 billion deal, but the cash offer has been extended and remains open for acceptances until March 6.

Mitchells & Butlers launched a GBP351 million open offer of shares to bolster its balance sheet as its "liquidity position has deteriorated significantly as a result of the impact of the Covid-19 pandemic".

The All Bar One owner said the extra cash will go towards reducing its unsecured debt. It also will support its secured debt financing.

As of mid-January, M&B had GBP113 million in cash balance with all its financing facilities drawn.

Its monthly cash burn during estate closures has been between GBP30 million and GBP35 million, and the company has GBP51 million in securitised debt servicing costs per quarter. The next quarterly payment is March 15.

CEO Phil Urban said: "M&B was a high performing business coming into the pandemic and with the support of our main stakeholders, including the equity injection from this Open Offer, we have every confidence that we can emerge in a strong competitive position once current restrictions are lifted.

"The hospitality industry has done everything that has been asked of it to date and, now that the vaccines are being rolled out and infections are dropping, we are hopeful that pubs and restaurants will soon be allowed to reopen safely."

Since the end of December, none of M&B's sites have been open. In the period between, September 27 and January 16, total managed sales were 70% lower annually.

Also getting new finance was IAG's British Airways. BA has secured a GBP2.0 billion UK Export Development Guarantee of GBP2.0 billion. The term-loan is for five years. British Airways also agreed a deferral of GBP450 million in pension deficit contributions to September.

Pubs, airlines and the wider travel & leisure industry will be in focus Monday as UK PM Johnson outlines how the Covid-19 curbs will be eased, paving the way for the first easing of restrictions since England's third national lockdown was announced on January 4.

All pupils in all years can go back to the classroom from March 8, with outdoor after-school sports and activities allowed to restart as well, Johnson is expected to say.

Socialising in parks and public spaces with one other person also will be permitted in a fortnight when the rules are relaxed to allow people to sit down for a drink or picnic.

However, Number 10 insisted that the "stay at home" message would remain in place despite the relaxation of some restrictions.

Sterling slipped below the USD1.40 mark as the dollar was higher across the board early Monday. The pound was quoted at USD1.3983, down slightly from USD1.4020 at the London equities close Friday.

The euro also lost ground on the dollar over the weekend. The single currency stood at USD1.2107 early Monday, down from USD1.2139 at the European equities close Friday. Against the yen, the dollar was trading at JPY105.75, improved from JPY105.53.

By Eric Cunha; ericcunha@alliancenews.com;

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.